Management of low (favourable)-risk prostate cancer

Research output: Research - peer-reviewArticle

Abstract

What's known on the subject? and What does the study add? Most men who are diagnosed with favourable-risk prostate cancer undergo some form of active intervention, despite evidence that treatment will not improve health outcomes for many. The decision to undergo treatment after diagnosis is, in part, related to the inability to precisely determine the long-term risk of harm without treatment. Nevertheless, physicians should consider patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments, before recommending a management option. This is especially important for older men, given the high level of evidence that those with low-risk disease are unlikely to accrue any benefit from curative intervention. What is known on the subject: Over treatment of favourable-risk prostate cancer is common, especially among older men. What does the study add: A review of the natural history of favourable-risk prostate cancer in the context of choices for management of the disease. The management of favourable-risk prostate cancer is controversial, and in the absence of controlled trials to inform best practice, choices are driven by personal beliefs with resultant wide variation in practice patterns. Men with favourable-risk prostate cancer diagnosed today often undergo treatments that will not improve overall health outcomes. A shared-decision approach for selecting optimal management of favourable-risk disease should account for patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments.

LanguageEnglish (US)
JournalBJU International
DOIs
StateAccepted/In press - 1800

Fingerprint

Prostatic Neoplasms
Therapeutics
cancer
management
Prostate cancer
Health
health
Disease
Risk Management
Neoplasms
evidence
Cancer
Health outcomes
Side effects
Disease Management
Practice Guidelines
Physicians
best practice
physician
history

Keywords

  • Favourable risk
  • Low risk
  • Prostate cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Organic Chemistry
  • Business, Management and Accounting(all)
  • Political Science and International Relations
  • Urology

Cite this

Management of low (favourable)-risk prostate cancer. / Carter, H. Ballentine.

In: BJU International, 1800.

Research output: Research - peer-reviewArticle

@article{9b97aa12d5384143bf3f6eb2a51b90fa,
title = "Management of low (favourable)-risk prostate cancer",
abstract = "What's known on the subject? and What does the study add? Most men who are diagnosed with favourable-risk prostate cancer undergo some form of active intervention, despite evidence that treatment will not improve health outcomes for many. The decision to undergo treatment after diagnosis is, in part, related to the inability to precisely determine the long-term risk of harm without treatment. Nevertheless, physicians should consider patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments, before recommending a management option. This is especially important for older men, given the high level of evidence that those with low-risk disease are unlikely to accrue any benefit from curative intervention. What is known on the subject: Over treatment of favourable-risk prostate cancer is common, especially among older men. What does the study add: A review of the natural history of favourable-risk prostate cancer in the context of choices for management of the disease. The management of favourable-risk prostate cancer is controversial, and in the absence of controlled trials to inform best practice, choices are driven by personal beliefs with resultant wide variation in practice patterns. Men with favourable-risk prostate cancer diagnosed today often undergo treatments that will not improve overall health outcomes. A shared-decision approach for selecting optimal management of favourable-risk disease should account for patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments.",
keywords = "Favourable risk, Low risk, Prostate cancer",
author = "Carter, {H. Ballentine}",
year = "1800",
doi = "10.1111/j.1464-410X.2011.10489.x",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Management of low (favourable)-risk prostate cancer

AU - Carter,H. Ballentine

PY - 1800

Y1 - 1800

N2 - What's known on the subject? and What does the study add? Most men who are diagnosed with favourable-risk prostate cancer undergo some form of active intervention, despite evidence that treatment will not improve health outcomes for many. The decision to undergo treatment after diagnosis is, in part, related to the inability to precisely determine the long-term risk of harm without treatment. Nevertheless, physicians should consider patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments, before recommending a management option. This is especially important for older men, given the high level of evidence that those with low-risk disease are unlikely to accrue any benefit from curative intervention. What is known on the subject: Over treatment of favourable-risk prostate cancer is common, especially among older men. What does the study add: A review of the natural history of favourable-risk prostate cancer in the context of choices for management of the disease. The management of favourable-risk prostate cancer is controversial, and in the absence of controlled trials to inform best practice, choices are driven by personal beliefs with resultant wide variation in practice patterns. Men with favourable-risk prostate cancer diagnosed today often undergo treatments that will not improve overall health outcomes. A shared-decision approach for selecting optimal management of favourable-risk disease should account for patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments.

AB - What's known on the subject? and What does the study add? Most men who are diagnosed with favourable-risk prostate cancer undergo some form of active intervention, despite evidence that treatment will not improve health outcomes for many. The decision to undergo treatment after diagnosis is, in part, related to the inability to precisely determine the long-term risk of harm without treatment. Nevertheless, physicians should consider patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments, before recommending a management option. This is especially important for older men, given the high level of evidence that those with low-risk disease are unlikely to accrue any benefit from curative intervention. What is known on the subject: Over treatment of favourable-risk prostate cancer is common, especially among older men. What does the study add: A review of the natural history of favourable-risk prostate cancer in the context of choices for management of the disease. The management of favourable-risk prostate cancer is controversial, and in the absence of controlled trials to inform best practice, choices are driven by personal beliefs with resultant wide variation in practice patterns. Men with favourable-risk prostate cancer diagnosed today often undergo treatments that will not improve overall health outcomes. A shared-decision approach for selecting optimal management of favourable-risk disease should account for patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments.

KW - Favourable risk

KW - Low risk

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=80052382828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052382828&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2011.10489.x

DO - 10.1111/j.1464-410X.2011.10489.x

M3 - Article

JO - BJU International

T2 - BJU International

JF - BJU International

SN - 1464-4096

ER -